These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1013 related items for PubMed ID: 18572750

  • 1. Long-term efficacy and safety of first-line therapy with once-daily saquinavir/ritonavir.
    Ananworanich J, Gayet-Ageron A, Ruxrungtham K, Chetchotisakd P, Prasithsirikul W, Kiertiburanakul S, Munsakul W, Raksakulkarn P, Tansuphasawadikul S, LeBraz M, Jupimai T, Ubolyam S, Schutz M, Hirschel B, Staccato Thailand Study Group.
    Antivir Ther; 2008; 13(3):375-80. PubMed ID: 18572750
    [Abstract] [Full Text] [Related]

  • 2. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.
    Cardiello P, Srasuebkul P, Hassink E, Mahanontharit A, Samor T, Ruxrungtham K, Lange J, Cooper D, Phanuphak P.
    HIV Med; 2005 Mar; 6(2):122-8. PubMed ID: 15807718
    [Abstract] [Full Text] [Related]

  • 3. A prospective study of efficacy and safety of once-daily saquinavir/ritonavir plus two nucleoside reverse transcriptase inhibitors in treatment-naive Thai patients.
    Ananworanich J, Hill A, Siangphoe U, Ruxrungtham K, Prasithsirikul W, Chetchotisakd P, Kiertiburanakul S, Munsakul W, Raksakulkarn P, Tansuphasawadikul S, Nuesch R, Cooper DA, Hirschel B, Staccato Study Group.
    Antivir Ther; 2005 Mar; 10(6):761-7. PubMed ID: 16218176
    [Abstract] [Full Text] [Related]

  • 4. Safety and efficacy of a double-boosted protease inhibitor combination, saquinavir and lopinavir/ritonavir, in pretreated children at 96 weeks.
    Bunupuradah T, van der Lugt J, Kosalaraksa P, Engchanil C, Boonrak P, Puthanakit T, Mengthaisong T, Mahanontharit A, Lumbiganon P, Tompkins E, Burger D, Ruxrungtham K, Ananworanich J, HIV-NAT 017 Study Team.
    Antivir Ther; 2009 Mar; 14(2):241-8. PubMed ID: 19430099
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes.
    Mootsikapun P, Chetchotisakd P, Anunnatsiri S, Boonyaprawit P.
    Antivir Ther; 2005 Mar; 10(8):911-6. PubMed ID: 16430196
    [Abstract] [Full Text] [Related]

  • 6. The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy.
    Staszewski S, Babacan E, Stephan C, Haberl A, Carlebach A, Gute P, Klauke S, Hermschulte Y, Stuermer M, Dauer B, Frankfurt HIV Cohort.
    J Antimicrob Chemother; 2006 Nov; 58(5):1024-30. PubMed ID: 16956902
    [Abstract] [Full Text] [Related]

  • 7. Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study.
    Gathe JC, Wood R, Sanne I, DeJesus E, Schürmann D, Gladysz A, Garris C, Givens N, Elston R, Yeo J.
    Clin Ther; 2006 May; 28(5):745-54. PubMed ID: 16861096
    [Abstract] [Full Text] [Related]

  • 8. A randomized trial comparing initial HAART regimens of nelfinavir/nevirapine and ritonavir/saquinavir in combination with two nucleoside reverse transcriptase inhibitors.
    Kirk O, Lundgren JD, Pedersen C, Mathiesen LR, Nielsen H, Katzenstein TL, Obel N, Gerstoft J.
    Antivir Ther; 2003 Dec; 8(6):595-602. PubMed ID: 14760893
    [Abstract] [Full Text] [Related]

  • 9. Double boosted protease inhibitors, saquinavir, and lopinavir/ritonavir, in nucleoside pretreated children at 48 weeks.
    Kosalaraksa P, Bunupuradah T, Engchanil C, Boonrak P, Intasan J, Lumbiganon P, Burger D, Ruxrungtham K, Schutz M, Ananworanich J, HIV-NAT 017 Study Team.
    Pediatr Infect Dis J; 2008 Jul; 27(7):623-8. PubMed ID: 18520443
    [Abstract] [Full Text] [Related]

  • 10. Long-term efficacy and safety of twice-daily saquinavir soft gelatin capsules (SGC), with or without nelfinavir, and three times daily saquinavir-SGC, in triple combination therapy for HIV infection: 100-week follow-up.
    Greenberg RN, Feinberg J, Goodrich J, Pilson RS, Siemon-Hryczyk P.
    Antivir Ther; 2003 Feb; 8(1):37-42. PubMed ID: 12713062
    [Abstract] [Full Text] [Related]

  • 11. A once-daily HAART regimen containing indinavir + ritonavir plus one or two nucleoside reverse transcriptase inhibitors (PIPO study).
    Burger DM, Aarnoutse RE, Dieleman JP, Gyssens IC, Nouwen J, de Marie S, Koopmans PP, Stek M, van der Ende ME.
    Antivir Ther; 2003 Oct; 8(5):455-61. PubMed ID: 14640393
    [Abstract] [Full Text] [Related]

  • 12. Inhibitory quotient as a prognostic factor of response to a salvage antiretroviral therapy containing ritonavir-boosted saquinavir. The CIVSA Study.
    Mallolas J, Blanco J, Labarga P, Vergara A, Ocampo A, Sarasa M, Arnedo M, López-Púa Y, García J, Juega J, Guelar A, Terrón A, Dalmau D, García I, Zárraga M, Martínez E, Carné X, Pumarola T, Escayola R, Gatell J.
    HIV Med; 2007 May; 8(4):226-33. PubMed ID: 17461850
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of ritonavir/indinavir 100/400 mg twice daily in combination with two nucleoside analogues in antiretroviral treatment-naive HIV-infected individuals.
    Duvivier C, Myrto A, Marcelin AG, Ghosn J, Ait-Mohand H, Schneider L, Agher R, Bricaire F, Costagliola D, Calvez V, Peytavin G, Katlama C.
    Antivir Ther; 2003 Dec; 8(6):603-9. PubMed ID: 14760894
    [Abstract] [Full Text] [Related]

  • 14. Ritonavir/saquinavir plus one nucleoside reverse transcriptase inhibitor (NRTI) versus indinavir plus two NRTIs in protease inhibitor-naive HIV-1-infected adults (IRIS study).
    Florence E, Dreezen C, Desmet P, Smets E, Fransen K, Vandercam B, Pelgrom J, Clumeck N, Colebunder R.
    Antivir Ther; 2001 Dec; 6(4):255-62. PubMed ID: 11878407
    [Abstract] [Full Text] [Related]

  • 15. Once-daily treatment with saquinavir mesylate (2000 mg) and ritonavir (100 mg) together with a fixed-dose combination of abacavir/lamivudine (600/300 mg) or tenofovir/emtricitabine (245/200 mg) in HIV-1-infected patients.
    Bickel M, Bodtländer A, Knecht GK, Stephan C, von Hentig N, Kurowski M, Gute P, Klauke S, Lutz T.
    J Antimicrob Chemother; 2009 Dec; 64(6):1260-4. PubMed ID: 19776037
    [Abstract] [Full Text] [Related]

  • 16. Comparison of once and twice daily dosing of didanosine in combination with stavudine for the treatment of HIV-1 infection. AI 454-146 Team.
    Monno L, Cargnel A, Soranzo ML, Chirianni A, Ferraro T, Di Stefano M, Angarano G.
    Antivir Ther; 1999 Dec; 4(4):195-202. PubMed ID: 10723498
    [Abstract] [Full Text] [Related]

  • 17. Safety and efficacy of ritonavir and saquinavir in combination with zidovudine and lamivudine.
    Michelet C, Bellissant E, Ruffault A, Arvieux C, Delfraissy JF, Raffi F, Bazin C, Renard I, Sébille V, Chauvin JP, Dohin E, Cartier F.
    Clin Pharmacol Ther; 1999 Jun; 65(6):661-71. PubMed ID: 10391672
    [Abstract] [Full Text] [Related]

  • 18. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
    Landman R, Capitant C, Descamps D, Chazallon C, Peytavin G, Katlama C, Pialoux G, Bentata M, Brun-Vézinet F, Aboulker JP, Yéni P, ANRS 127 Study Group.
    J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
    [Abstract] [Full Text] [Related]

  • 20. Once-daily dosing of saquinavir soft-gel capsules and ritonavir combination in HIV-1-infected patients (IMEA015 study).
    Lamotte C, Landman R, Peytavin G, Mentre F, Gerbe J, Brun-Vezinet F, Boue F, Spiridon G, Valantin MA, Michelet C, Farinotti R, Yeni P.
    Antivir Ther; 2004 Apr; 9(2):247-56. PubMed ID: 15134187
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 51.